Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis by Cai Yu, Yi Jiayong, Zhou Chaohui, Shen Xizhong in PloS one (2012).

[PMID: 23082213] PubMed


Three first-line antituberculosis drugs, isoniazid, rifampicin and pyrazinamide, may induce liver injury, especially isoniazid. This antituberculosis drug-induced liver injury (ATLI) ranges from a mild to severe form, and the associated mortality cases are not rare. In the past decade, many investigations have focused the association between drug-metabolising enzyme (DME) gene polymorphisms and risk for ATLI; however, these studies have yielded contradictory results.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.